
    
      The study consists of two parts: the ASC22 single-dose IIa study and the ASC22 multi-dose IIb
      study. The IIa study consists of 3 cohorts of 0.3mg/kg, 1.0mg/kg and 2.5mg/kg, and the IIb
      study consists of 2 cohorts of 1.0mg/kg and 2.5mg/kg. The objective is to evaluate the
      safety, tolerance and efficacy of ASC22 in patients with chronic hepatitis B (CHB), and to
      provide a guidance for the determination of dosage regimen.
    
  